Premium
A phase I‐II study of dacarbazine in combination with outpatient interleukin‐2 in metastatic malignant melanoma
Author(s) -
Flaherty Lawrence E.,
Redman Bruce G.,
Chabot Guy G.,
Martino Silvana,
Gualdoni Steven M.,
Heilbrun Lance K.,
Valdivieso Manuel,
Bradley Edward C.
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900601)65:11<2471::aid-cncr2820651113>3.0.co;2-f
Subject(s) - medicine , dacarbazine , melanoma , regimen , toxicity , interleukin 2 , gastroenterology , progressive disease , immunotherapy , phases of clinical research , chemotherapy , surgery , oncology , cancer , cytokine , cancer research
Because of encouraging response rates published with recombinant interleukin‐2 (rIL‐2) alone in metastatic malignant melanoma (MMM), dacarbazine (DTIC) and rIL‐2 were sequentially combined to evaluate efficacy, toxicity, pharmacokinetics, and immunologic interaction. Thirty‐two patients aged 18 to 67 years have received 127 courses of treatment. The dose of DTIC was 1.0 g/m 2 as a 24‐hour infusion every 28 days on day 1. Recombinant interleukin‐2 (2.0, 3.0, 4.0, or 5.0 × 10 6 Cetus units/m 2 ) was administered as a 30‐minute infusion on days 15 through 19 and 22 through 26 of each 28‐day cycle. Seven of 32 patients (22%) who received therapy had a remission, one complete and six partial. The complete response was in a lung mass. Partial responses were seen in lymph nodes, liver, and lung. The median duration of response was 4.7 months. One patient is in persistent partial remission of the liver for greater than 2 years. One patient had residual mediastinal disease resected after partial response and remains without evidence of disease for 18+ months. This regimen was generally well tolerated, did not create overlapping toxicity, and produced encouraging responses in visceral sites. This provides a framework for future combinations of chemotherapy with rIL‐2 alone or in combination with other biologic response modifiers in an outpatient setting.